UCLA researchers identify possible approach to prevent cancer from evolving to resist treatment

Blood tests show potential for CRC detection, but follow-up falls short

About half patients completed a follow-up colonoscopy within six months of taking a blood-based colorectal cancer screening test, according to a study by investigators at UCLA Health Jonsson Comprehensive Cancer Center.

August 01, 2025

Vol.51 No.30

In Brief

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor-induced type 1 diabetes using an existing class of autoimmune drugs.

UCLA study identifies key protein that helps liver cancer resist heat-based treatment

Galectin-1, a sugar-binding protein, plays a critical role in helping hepatocellular carcinoma resist thermal ablation and even thrive after being treated with high heat, according to a study from investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

Cardiac biomarkers linked to future cancer risk, even without heart disease, says UCLA prospective cohort study

Certain cardiac blood markers can strongly predict future cancer risk—even in people with no history or symptoms of heart disease, according to a UCLA Health study.